icad inc. (ICAD) News
Filter ICAD News Items
ICAD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ICAD News From Around the Web
Below are the latest news stories about ICAD INC that investors may wish to consider to help them evaluate ICAD as an investment opportunity.
SABCS 2024: New Research Assesses iCAD’s Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse PopulationsReveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological TreatmentNASHUA, N.H., Dec. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that four novel AI-driven breast cancer research abstracts have been accepted for presentation at the 2024 San Antonio Breast Ca |
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025NASHUA, N.H., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Further to a release issued under the same headline on November 26, 2024 13:00 ET by iCAD, Inc., the headline and fourth paragraph have been updated to acknowledge a pending trademark application for the mark “SecondReadAI” by Lunit, Inc. The corrected release follows: iCAD, Inc. (NASDAQ: ICAD) (“iCAD” |
US Penny Stocks To Watch In December 2024As the U.S. market takes a breather from its post-election rally, major indices like the Dow Jones and S&P 500 are seeing slight declines while still riding high on recent record achievements. In this context, penny stocks—often smaller or newer companies—remain an intriguing investment area despite their somewhat outdated label. These stocks can offer unique growth opportunities, especially when backed by solid financials, making them worthy of attention for investors seeking under-the-radar... |
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025NASHUA, N.H., Nov. 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, December 1-5. Key highlight |
Need To Know: Analysts Just Made A Substantial Cut To Their iCAD, Inc. (NASDAQ:ICAD) EstimatesThe latest analyst coverage could presage a bad day for iCAD, Inc. ( NASDAQ:ICAD ), with the analysts making... |
iCAD Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagiCAD ( NASDAQ:ICAD ) Third Quarter 2024 Results Key Financial Results Revenue: US$4.22m (up 3.5% from 3Q 2023). Net... |
Q3 2024 ICAD Inc Earnings CallQ3 2024 ICAD Inc Earnings Call |
Icad: Q3 Earnings SnapshotNASHUA, N.H. (AP) — Icad inc. ICAD) on Wednesday reported a loss of $1.8 million in its third quarter. The Nashua, New Hampshire-based company said it had a loss of 7 cents per share. |
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2024. Third Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.3 million, up 10% year over yearTotal revenues were $4.2 million, up 4% year o |
iCAD's ProFound Detection Version 4.0 Gains FDA ClearanceProvides 22% Overall Improvement in Detecting Challenging and Aggressive Cancer Subtypes and Enables Clinicians to Incorporate a Prior Exam into Current Screening AnalysisNASHUA, N.H., Nov. 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that its ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT) has received clearance from the U.S. Food and Drug Adminis |